Corporate Symposium (CS01) | Novocure

TTFields future perspectives within and beyond neuro-oncology (click title to view PDF invitation)

Friday, September 16, 13:15 - 14:30 hrs, Festaal

Tumor Treating Fields (TTFields) is a non-invasive treatment modality initially approved in the field of neuro-oncology. Novocure® is committed to the continued development of the technology while exploring its further application for the treatment of other solid tumor indications.

This lunchtime symposium ‘TTFields – within and beyond neuro-oncology’ will bring together a panel of experts across various oncology disciplines, chaired by Prof. med Michael Weller and Prof. med Lukas Weiss. The four talks and accompanying discussions will cover study updates, as well as present and future applications of TTFields that are in the clinical pipeline.

Along with surgery, systemic therapies and radiotherapy, TTFields provide a novel approach to treating tumours. The horizons of TTFields is ever-expanding and therefore this symposium should provide valuable and relevant insights to many attendees at EANO.

© 2022 Novocure GmbH. All rights reserved. Novocure is a registered trademark of Novocure GmbH. September 2022. EU-SRC-0209

Corporate Symposium (CS02) | Alexion

Plexiform neurofibromas (PNs) associated with NF1: Clinical cases and MDT approach in decision making (click title to view PDF invitation)

Friday, September 16, 13:15 - 14:15 hrs

Programme Synopsis

• Plexiform neurofibromas (PNs) present in 30-50% of patients with neurofibromatosis type 1 (NF1). PNs typically manifest early, developing rapidly in early childhood and have the potential to cause significant pain, disability, and disfigurement, depending on their location and size.
• Historically, the only treatment for PNs was surgery, but some are difficult to fully resect due to tissue infiltration and hypervascularisation. More recently MEK inhibitors have been investigated as a therapeutic option for the treatment of inoperable NF1-PNs.
• This Symposium will discuss the current landscape and treatment options of patients with NF1 PNs using case studies with a team of highly experienced and distinguished MDT physicians followed by an audience Q&A.

Veeva ID: M/INT/KOS-NF1/0037. Date of preparation: August 2022

This is a non promotional industry symposium, funded and organised by Alexion. Please note, data relating to an Alexion product will be presented at this meeting. Product registration conditions differ internationally, and prescribing information may vary depending on approval in each country. This meeting is intended for healthcare professionals only.

Corporate Symposium (CS03) | 10xGenomics

Single cell and spatial transcriptomic methods to understand neuro-oncology (click title to view PDF invitation)

Friday, September 16, 18:45 - 19:45 hrs, Forum

Corporate Symposium (CS04) | Blue Earth Diagnostics

PET Imaging for Primary Brain Tumours and CNS Metastases (click title to view PDF invitation)

Saturday, September 17, 13:00 - 14:00 hrs, Zeremoniensaal

This scientific symposium is fully funded and sponsored by Blue Earth Diagnostics Ltd.

For the management of patients with both primary and secondary brain tumours, clinicians frequently need to rely on information obtained from magnetic resonance imaging (MRI) throughout the disease continuum. However, in the peri- and post-treatment settings, MRI has limited specificity due to the incidence of treatment-related changes. These include radiation necrosis, particularly in post-stereotactic radiosurgery brain metastases, and pseudoprogression, particularly in post-treatment Glioblastoma Multiforme and post-immunotherapy brain metastases. Positron emission tomography (PET) represents a potential solution over conventional, structural imaging to obtain a non-invasive imaging diagnosis of disease recurrence / tumour progression versus treatment-related changes. While 18F-FDG has limited intracranial utility due to high physiologic uptake in normal brain parenchyma, amino acid (AA) PET radiotracers can potentially overcome the limitations of FDG. The symposium aims to initiate discussion on the role of AA PET tracers for primary brain tumours and central nervous system metastases.

PP-EU-0097 / August 2022

Corporate Symposium (CS05) | Carthera

Overcoming the BBB using ultrasound – first in human and translational results (click title to view PDF invitation)

Saturday, September 17, 13:00 - 14:00 hrs, Forum

Over the past several decades, a wide variety of technologies have been explored to overcome the blood-brain barrier (BBB). Some of these have shown clinical benefit, but with technical limitations that have hampered their widespread adoption. The treatment of GBM is particularly affected by the inability of therapeutic compounds to reach infiltrated glioma cells at an effective concentration. BBB disruption using low-intensity pulsed ultrasound (LIPU) offers new hope in this field. SonoCloud, an implantable ultrasound device that overcomes the limitations of previous techniques, is currently being evaluated in clinical trials in Europe and the United States, with more than 450 treatments performed to date. An overview of nonclinical and clinical safety and efficacy data will be covered. This symposium will also be an opportunity to discuss new therapeutic perspectives opened by this technology.

Corporate Symposium (CS06) | Chimerix

ONC201 in H3 K27M-Mutant Diffuse Glioma (click title to view PDF invitation)

Saturday, September 17, 13:00 - 14:00 hrs, Künstlerzimmer

H3 K27M-mutant diffuse glioma has an exceptionally poor prognosis, and no approved systemic therapies are available.  ONC201 (Chimerix, Inc.) is an oral, blood-brain barrier penetrating, small molecule antagonist of DRD2/3 and agonist of the mitochondrial protease ClpP. In preclinical and early phase analyses, ONC201 showed efficacy in H3 K27M-mutant diffuse glioma.  A subsequent integrated efficacy analysis by blinded independent central review of open-label ONC201 studies demonstrated overall response rates of 20% (95%CI, 10-34) by RANO-HGG and 30% (95%CI, 18-45) by RANO-HGG and/or RANO-LGG criteria.  With no identified dose-limiting toxicities or treatment-related discontinuations, ONC201 appears to be safe and well-tolerated.  An upcoming randomized phase 3 trial will evaluate the safety and efficacy ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma.  This symposium will provide background on ONC201 mechanism of action, currently available efficacy and safety data, and the design and enrollment criteria for the forthcoming phase 3 trial.

Corporate Symposium (CS07) | Illumina

Development and use of DNA methylation profiling for CNS Tumor classification (click title to view PDF invitation)

Saturday, September 17, 17:30 - 18:00 hrs, Forum

Speaker: Felix Sahm, Germany